Innovation
Innovation
Improving Health for All
We develop new ways to promote faster development of valuable treatments and ensure diverse patient groups can access them.
Featured White Paper
The Elasticity of Pharmaceutical Innovation: How Much Does Revenue Drive New Drug Development?
For every 10% reduction in expected revenues, we can expect 2.5% to 15% less pharmaceutical innovation. Policymakers should take care to balance reductions in health outcomes long-term with short-term access improvements.
Experts: Karen Van Nuys, Darius Lakdawalla, Dana Goldman
Top Innovation Stories View All
Comment Letter
Comments on National Coverage Analysis: Transcatheter Aortic Valve Replacement and Broader CED Policy Considerations
Featured Experts: Darius Lakdawalla, Barry Liden
In The News View All
Axios
Schiller says China’s rise in drug development could upend U.S. R&D models
Featured Experts: Lowell Schiller
STAT News
Kanter tracks decline in FDA public advisory committee meetings
Featured Experts: Genevieve P. Kanter
Regulatory Focus
Kanter interviewed about the questionable legal basis for FDA’s ad hoc expert panels
Featured Experts: Genevieve P. Kanter
Bloomberg
Lakdawalla argues for a drug pricing system aligned with American values
Featured Experts: Darius Lakdawalla
MedPage Today
Kanter discusses changes in staffing and decision-making at the FDA
Featured Experts: Genevieve P. Kanter
Related Subtopics
High drug prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. We connect industry, academia and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Team View All Innovation Experts
